-
2024-514687-33-00
4
2021-12-21
Previously Untreated Chronic Lymphophatic Leukaemia
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-507202-14-00
7
2021-04-29
Upper limb spasticity after stroke or traumatic brain injury
-
2023-510515-19-00
5
2020-11-27
Higher-risk-myelodysplastic syndromes
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-504888-16-00
9
2020-10-05
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
-
2024-516612-16-00
4
2020-06-17
gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)
-
2024-517200-10-00
4
2020-01-31
Advanced non-small-cell lung cancer
-
2023-510516-39-00
4
2019-10-30
Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-518901-16-00
4
2019-07-29
RIS (Radiologically Isolated Syndrome)
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2024-512292-12-00
6
2019-02-20
Low Back Pain
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-517091-38-00
3
2025-11-25
Head and neck squamous cell carcinoma
-
2025-521249-25-00
7
2025-10-30
MTAP-deleted advanced or metastatic solid tumors
-
2024-520050-38-00
5
2025-09-18
Extensive stage small cell lung cancer (ES-SCLC). S
-
2024-520031-33-00
4
2025-09-16
Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
-
2024-516412-17-00
5
2025-08-26
Developmental and Epileptic Encephalopathies (DEE)